Efficacy of rituximab in hairy cell leukemia treatment. 2000

P L Zinzani, and S Ascani, and P P Piccaluga, and M Bendandi, and S Pileri, and S Tura

UI MeSH Term Description Entries
D007943 Leukemia, Hairy Cell A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow. Hairy Cell Leukemia,Leukemic Reticuloendotheliosis,Reticuloendotheliosis, Leukemic,Hairy Cell Leukemias,Leukemias, Hairy Cell,Leukemic Reticuloendothelioses,Reticuloendothelioses, Leukemic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069283 Rituximab A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. CD20 Antibody, Rituximab,GP2013,IDEC-C2B8,IDEC-C2B8 Antibody,Mabthera,Rituxan,IDEC C2B8,IDEC C2B8 Antibody,Rituximab CD20 Antibody
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D058846 Antibodies, Monoclonal, Murine-Derived Antibodies obtained from a single clone of cells grown in mice or rats. Murine-Derived Monoclonal Antibodies,Antibodies, Murine-Derived Monoclonal,Monoclonal Antibodies, Murine-Derived,Murine Derived Monoclonal Antibodies

Related Publications

P L Zinzani, and S Ascani, and P P Piccaluga, and M Bendandi, and S Pileri, and S Tura
May 2006, Presse medicale (Paris, France : 1983),
P L Zinzani, and S Ascani, and P P Piccaluga, and M Bendandi, and S Pileri, and S Tura
August 2005, Leukemia & lymphoma,
P L Zinzani, and S Ascani, and P P Piccaluga, and M Bendandi, and S Pileri, and S Tura
August 2009, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
P L Zinzani, and S Ascani, and P P Piccaluga, and M Bendandi, and S Pileri, and S Tura
June 2008, Ugeskrift for laeger,
P L Zinzani, and S Ascani, and P P Piccaluga, and M Bendandi, and S Pileri, and S Tura
December 2003, Blood,
P L Zinzani, and S Ascani, and P P Piccaluga, and M Bendandi, and S Pileri, and S Tura
January 2014, The New England journal of medicine,
P L Zinzani, and S Ascani, and P P Piccaluga, and M Bendandi, and S Pileri, and S Tura
March 2012, Leukemia & lymphoma,
P L Zinzani, and S Ascani, and P P Piccaluga, and M Bendandi, and S Pileri, and S Tura
July 2021, Cancer discovery,
P L Zinzani, and S Ascani, and P P Piccaluga, and M Bendandi, and S Pileri, and S Tura
November 2013, Clinical cancer research : an official journal of the American Association for Cancer Research,
P L Zinzani, and S Ascani, and P P Piccaluga, and M Bendandi, and S Pileri, and S Tura
June 2015, Annals of hematology,
Copied contents to your clipboard!